Skip to main content
NCD 210.13 · version 1

NCD 210.13: Screening for Hepatitis C Virus (HCV) in Adults

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database NCDs: API snapshot September 27, 2026 (effective September 20, 2026). Next CMS release: weekly, every Thursday.

Medicare Coverage Database NCDs: the loaded version is API snapshot September 27, 2026, and the CMS schedule called for a newer one from October 1, 2026. Verify figures against the current CMS publication until this reference is rebuilt; pages built on it are withdrawn from search indexing until then.

Key facts for NCD 210.13

Benefit category
Additional Preventive Services
Effective date
06/02/2014
Implemented 01/05/2015
Transmittal
Transmittal 177
Versions published
1
Manual section
210
Prevention, NCD Manual (Pub. 100-03) chapter 1 part 4

TL;DR

NCD 210.13 sets Medicare's national policy for screening for hepatitis c virus (hcv) in adults under the benefit category "Additional Preventive Services", effective 06/02/2014 and implemented 01/05/2015. Effective for services performed on or after June 2, 2014, CMS has determined the following: It has been revised once since publication and binds every Medicare Administrative Contractor nationally.

Item or service described

A. General

Hepatitis C Virus (HCV) is an infection that attacks the liver and leads to inflammation. The infection is often asymptomatic and can go undiagnosed for decades. It is difficult for the human immune system to eliminate the HCV and it is a major cause of chronic liver disease. The presence of HCV in the liver initiates a response from the immune system which in turn causes inflammation. Inflammation over long periods of time (usually decades) can cause scarring, called cirrhosis. A cirrhotic liver fails to perform the normal functions of the liver which leads to liver failure. Cirrhotic livers are more prone to become cancerous and liver failure leads to serious complications, even death. HCV is reported to be the leading cause of chronic hepatitis, cirrhosis and liver cancer and a primary indication for liver transplant in the Western World.

Under §1861(ddd) of the Social Security Act (the Act), the Centers for Medicare & Medicaid Services (CMS) has the authority to add coverage of additional preventive services if certain statutory requirements are met. The regulations provide:

42 CFR §410.64 Additional preventive services

(a) Medicare Part B pays for additional preventive services not described in paragraph (1) or (3) of the definition of “preventive services” under 42 CFR §410.2, that identify medical conditions or risk factors for individuals if the Secretary determines through the national coverage determination process (as defined in section 1869(f)(1)(B) of the Act) that these services are all of the following: (1) reasonable and necessary for the prevention or early detection of illness or disability,(2) recommended with a grade of A or B by the United States Preventive Services Task Force (USPSTF), (3) appropriate for individuals entitled to benefits under Part A or enrolled under Part B.

(b) In making determinations under paragraph (a) of this section regarding the coverage of a new preventive service, the Secretary may conduct an assessment of the relation between predicted outcomes and the expenditures for such services and may take into account the results of such an assessment in making such national coverage determinations.

The scope of the review for this national coverage determination (NCD) evaluated and determined if the existing body of evidence was sufficient for Medicare coverage for screening for HCV in adults at high risk for HCV infection and one-time screening for HCV infection for adults born between 1945 and 1965, which is recommended with a grade B by the USPSTF.

Indications and limitations of coverage

B. Nationally Covered Indications

Effective for services performed on or after June 2, 2014, CMS has determined the following:

The evidence is adequate to conclude that screening for HCV, consistent with the grade B recommendations by the USPSTF, is reasonable and necessary for the prevention or early detection of an illness or disability and is appropriate for individuals entitled to benefits under Part A or enrolled under Part B, as described below.

Therefore, CMS will cover screening for HCV with the appropriate U.S. Food and Drug Administration (FDA)-approved/cleared laboratory tests, used consistent with FDA-approved labeling and in compliance with the Clinical Laboratory Improvement Act regulations, when ordered by the beneficiary’s primary care physician or practitioner within the context of a primary care setting, and performed by an eligible Medicare provider for these services, for beneficiaries who meet either of the following conditions:

• A screening test is covered for adults at high risk for HCV infection. “High risk” is defined as persons with a current or past history of illicit injection drug use; and persons who have a history of receiving a blood transfusion prior to 1992. Repeat screening for high risk persons is covered annually only for persons who have had continued illicit injection drug use since the prior negative screening test.

• A single screening test is covered for adults who do not meet the high risk definition above, but who were born from 1945 through 1965.

The determination of “high risk for HCV” is identified by the primary care physician or practitioner who assesses the patient’s history, which is part of any complete medical history, typically part of an annual wellness visit and considered in the development of a comprehensive prevention plan. The medical record should be a reflection of the service provided.

A primary care setting is defined by the provision of integrated, accessible health care services by clinicians who are accountable for addressing a large majority of personal health care needs, developing a sustained partnership with patients, and practicing in the context of family and community. Emergency departments, inpatient hospital settings, ambulatory surgical centers, independent diagnostic testing facilities, skilled nursing facilities, inpatient rehabilitation facilities, clinics providing a limited focus of health care services, and hospice are examples of settings not considered primary care settings under this definition.

A “primary care physician” and “primary care practitioner” will be defined consistent with existing sections of the Act (§1833(u)(6), §1833(x)(2)(A)(i)(I) and §1833(x)(2)(A)(i)(II)).

§1833(u)

(6) Physician Defined.—For purposes of this paragraph, the term “physician” means a physician described in section 1861(r)(1) and the term “primary care physician” means a physician who is identified in the available data as a general practitioner, family practice practitioner, general internist, or obstetrician or gynecologist.

§1833(x)(2)(A)(i)

(I) is a physician (as described in section 1861(r)(1)) who has a primary specialty designation of family medicine, internal medicine, geriatric medicine, or pediatric medicine; or

(II) is a nurse practitioner, clinical nurse specialist, or physician assistant (as those terms are defined in section 1861(aa)(5)).

C. Nationally Non-Covered Indications

Unless specifically covered in this NCD, any other NCD, or in statute, preventive services are non-covered by Medicare.

D. Other

N/A

(This NCD last reviewed June 2014.)

Text reproduced from the CMS Medicare Coverage Database record for NCD 210.13 version 1. View the original on cms.gov.

Local policies that build on this NCD

4 active Local Coverage Determinations cite NCD 210.13 among their related national policies. An LCD may not conflict with the national determination; read it for the contractor's documentation and coding detail in that jurisdiction.

  • LCD L39044: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing · Wisconsin Physicians Service Insurance Corporation
  • L38988 MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing · Palmetto GBA
  • L39001 MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing · Noridian Healthcare Solutions, LLC
  • L39038 MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing · CGS Administrators, LLC

How MACs bill NCD 210.13

A National Coverage Determination states the policy; the Medicare Administrative Contractors publish the articles that turn it into claim edits. 4 current articles in the Medicare Coverage Database name NCD 210.13, 4 of them with a covered ICD-10-CM list, from 4 contractors. The lists can differ by contractor even though the NCD is national, because each MAC codes the policy for its own claims system; check the article of the contractor that processes the claim.

A58710: Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing

Billing and Coding, effective 2026-08-06 · Palmetto GBA (10111, 10112, 10211, 10212, 10311, 10312, 11201, 11202, 11301, 11302, 11401, 11402, 11501, 11502) · CMS record

851 covered ICD-10-CM codes in 11 groups; 137 procedure codes: 0068U, 0096U, 0109U, 0115U, 0140U, 0141U, 0142U, 0202U, 0223U, 0225U, 0301U, 0302U and 125 more. Local policy: L38988 MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing. Check a diagnosis for 0068U.

First covered codes: A37.00 Whooping cough due to Bordetella pertussis without pneumonia; A37.01 Whooping cough due to Bordetella pertussis with pneumonia; A37.10 Whooping cough due to Bordetella parapertussis without pneumonia; A37.11 Whooping cough due to Bordetella parapertussis with pneumonia; A37.80 Whooping cough due to other Bordetella species without pneumonia; A37.81 Whooping cough due to other Bordetella species with pneumonia; …

A58720: Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing

Billing and Coding, effective 2026-08-06 · Noridian Healthcare Solutions, LLC (01111, 01112, 01182, 01211, 01212, 01311, 01312, 01911, 02101, 02102, 02201, 02202, 02301, 02302, 02401, 02402, 03101, 03102, 03201, 03202, 03301, 03302, 03401, 03402, 03501, 03502, 03601, 03602) · CMS record

851 covered ICD-10-CM codes in 11 groups; 137 procedure codes: 0068U, 0096U, 0109U, 0115U, 0140U, 0141U, 0142U, 0202U, 0223U, 0225U, 0301U, 0302U and 125 more. Local policy: L39001 MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing. Check a diagnosis for 0068U.

First covered codes: A37.00 Whooping cough due to Bordetella pertussis without pneumonia; A37.01 Whooping cough due to Bordetella pertussis with pneumonia; A37.10 Whooping cough due to Bordetella parapertussis without pneumonia; A37.11 Whooping cough due to Bordetella parapertussis with pneumonia; A37.80 Whooping cough due to other Bordetella species without pneumonia; A37.81 Whooping cough due to other Bordetella species with pneumonia; …

A58747: Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing

Billing and Coding, effective 2026-05-14 · CGS Administrators, LLC (15101, 15102, 15201, 15202) · CMS record

852 covered ICD-10-CM codes in 11 groups; 137 procedure codes: 0068U, 0096U, 0109U, 0115U, 0140U, 0141U, 0142U, 0202U, 0223U, 0225U, 0301U, 0302U and 125 more. Local policy: L39038 MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing. Check a diagnosis for 0068U.

First covered codes: A37.00 Whooping cough due to Bordetella pertussis without pneumonia; A37.01 Whooping cough due to Bordetella pertussis with pneumonia; A37.10 Whooping cough due to Bordetella parapertussis without pneumonia; A37.11 Whooping cough due to Bordetella parapertussis with pneumonia; A37.80 Whooping cough due to other Bordetella species without pneumonia; A37.81 Whooping cough due to other Bordetella species with pneumonia; …

A58761: Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing

Billing and Coding, effective 2026-08-06 · Wisconsin Physicians Service Insurance Corporation (05101, 05102, 05201, 05202, 05301, 05302, 05401, 05402, 05901, 08101, 08102, 08201, 08202) · CMS record

851 covered ICD-10-CM codes in 11 groups; 137 procedure codes: 0068U, 0096U, 0109U, 0115U, 0140U, 0141U, 0142U, 0202U, 0223U, 0225U, 0301U, 0302U and 125 more. Local policy: L39044 MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing. Check a diagnosis for 0068U.

First covered codes: A37.00 Whooping cough due to Bordetella pertussis without pneumonia; A37.01 Whooping cough due to Bordetella pertussis with pneumonia; A37.10 Whooping cough due to Bordetella parapertussis without pneumonia; A37.11 Whooping cough due to Bordetella parapertussis with pneumonia; A37.80 Whooping cough due to other Bordetella species without pneumonia; A37.81 Whooping cough due to other Bordetella species with pneumonia; …

Coverage analysis history

CMS opens a national coverage analysis (NCA) to create or reconsider an NCD; the analysis carries a CAG tracking number, the evidence review and the decision memo. The Medicare Coverage Database links 2 analyses to NCD 210.13, listed here in the order CMS opened them (by NCA record number). A reconsideration ("Recon") revisits an earlier decision; an analysis whose status is open is still in progress.

  1. CAG-00436N Screening for Hepatitis C Virus (HCV) in Adults (New, Closed)
  2. CAG-00436R Screening for Hepatitis C Virus (HCV) in Adults (1st Recon, Open For Public Comment)

Revision history

02/2026 - The purpose of this Change Request (CR) is to clarify billing requirements for NCD 210.13 Screening for HCV in adults. ( TN 13633 ) (CR14388)

07/2025 - The purpose of this Change Request (CR) is to provide a quarterly maintenance update of ICD-10 coding conversions and other coding updates specific to NCDs. No policy is being changed as a result of these updates. ( TN 13327 ) (CR14041)

06/2025 - The purpose of this Change Request (CR) is to provide an update for contractors to make the appropriate coding modifications specific to HETS required for the Hepatitis C Virus National Coverage Determination (NCD) 210.13. ( TN 13244 ) (CR14092)

06/2025 - The purpose of this Change Request (CR) is to provide a quarterly maintenance update of ICD-10 coding conversions and other coding updates specific to NCDs. No policy is being changed as a result of these updates. ( TN 13251 ) (CR14041)

07/2017 - This Change Request (CR) constitutes a maintenance update of International Code of Diseases, Tenth Revision (ICD-10) conversions and other coding updates specific to National Coverage Determinations (NCDs). These NCD coding changes are the result of newly available codes, coding revisions to NCDs released separately, or coding feedback received.

Previous NCD coding changes appear in ICD-10 quarterly updates that can be found at: https://www.cms.gov/Medicare/Coverage/CoverageGenInfo/ICD10.html , along with other CRs implementing new policy NCDs. Edits to ICD-10 and other coding updates specific to NCDs will be included in subsequent quarterly releases and individual CRs as appropriate. No policy-related changes are included with the ICD-10 quarterly updates. Any policy-related changes to NCDs continue to be implemented via the current, long-standing NCD process. ( TN 1875 ) (CR10184)

05/2017 - This change request (CR) constitutes a maintenance update of ICD-10 conversions and other coding updates specific to national coverage determinations (NCDs). These NCD coding changes are the result of newly available codes, coding revisions to NCDs released separately, or coding feedback received.

Previous NCD coding changes appear in ICD-10 quarterly updates that can be found at: https://www.cms.gov/Medicare/Coverage/CoverageGenInfo/ICD10.html , along with other CRs implementing new policy NCDs. Edits to ICD-10 and other coding updates specific to NCDs will be included in subsequent, quarterly releases and individual CRs as appropriate. No policy-related changes are included with the ICD-10 quarterly updates. Any policy-related changes to NCDs continue to be implemented via the current, long-standing NCD process. ( TN 1854 ) (CR10086)

09/2014 - Effective for services performed on or after June 2, 2014, the Centers for Medicare & Medicaid Services will cover screening for hepatitis C virus consistent with the grade B recommendations by the USPSTF for the prevention or early detection of an illness or disability and is appropriate for individuals entitled to benefits under Medicare Part A or enrolled under Part B. Effective date: 06/02/2014 Implementation date: 01/05/2015. ( TN 174 ) (CR8871)

11/2014 - Transmittal 174 dated September 5, 2014, is being rescinded and replaced by Transmittal 177 to make minor editorial revisions to the 'Policy' section of the attached business requirements. All other information remains the same. ( TN 177 ) (CR8871)

How this NCD shows up on remittances

A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.

For teams evaluating QuickIntell software

Evaluate a coverage-review workflow around NCD 210.13

Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — NCD 210.13

What does NCD 210.13 cover?

Effective for services performed on or after June 2, 2014, CMS has determined the following: The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.

When did NCD 210.13 take effect?

The current version (1) is effective 06/02/2014, implemented 01/05/2015, published in transmittal 177. This is the only published version.

Does a Local Coverage Determination override NCD 210.13?

No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.